Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 4/20 | 0.52 |
| ▸ | ADH1A | P07327 | 4/20 | 0.52 |
| ▸ | ADH1C | P00326 | 3/20 | 0.48 |
| ▸ | ADH7 | P40394 | 2/20 | 0.48 |
| ▸ | ADH4 | P08319 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928027 | 0.88 | ADH1B (0.43) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL28313628 | 0.81 | GNAI3 (0.50) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL28267489 | 0.80 | GNAO1 (0.56) | ADH1BADH1AADH1CADH7EPHX1 | |
| SCHEMBL23741025 | 0.79 | ADH1B (0.46) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL14504027 | 0.79 | ADH1B (0.46) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL172647 | 0.77 | ADH1B (0.40) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL3926638 | 0.77 | ADH1B (0.47) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL3343259 | 0.76 | ADH1B (0.48) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL1307156 | 0.76 | ADH1B (0.48) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL23973906 | 0.76 | TSHR (0.49) | ADH1BADH1AADH1CADH7ADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | claimed |
| WO-2009024825-A1 | 2-PYRAZINYLBENZIMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | claimed |
| CN-110105346-A | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2019-08-09 | — | — | CN | disclosed |
| CN-106414432-B | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2019-06-14 | — | — | CN | disclosed |
| EP-2799435-B1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | CHENGDU DIAO PHARMACEUTICAL GROUP CO LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| US-9187430-B2 | Poly (ADP-ribose) polymerase inhibitor | CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-11-17 | — | — | US | disclosed |
| US-20150051211-A1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-02-19 | — | — | US | disclosed |
| EP-2799435-A1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | Chengdu Di'ao Pharmaceutical Group Co. Ltd. (CN) | 2014-11-05 | — | — | EP | disclosed |
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
| EP-2212326-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009024824-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024825-A1 | 2-PYRAZINYLBENZIMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009007390-A2 | 2-PYRAZ INYLBENZ IMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | ADH1B 4400/4885ADH1A 3780/4885ADH1C 3268/4885 |
| US-20150051211-A1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | PARP1, PARP2, PARP11 | ADH1B 611/4885ADH1A 1292/4885ADH1C 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.